oligoprogression on alectinib: next steps - lung cancer onctalk 2022
Published 1 year ago • 47 plays • Length 2:40Download video MP4
Download video MP3
Similar videos
-
7:35
current treatments for oligometastatic nsclc - lung cancer onctalk 2022
-
3:14
stereotactic body radiotherapy (sbrt) for oligoprogressive nsclc - onctalk lung 2023
-
4:10
overcoming resistance in alk or kras nsclc - lung cancer onctalk 2022
-
6:40
studies in oligometastatic nsclc: current data and definitions - lung cancer onctalk 2022
-
2:30
advances in oligometastatic disease - onctalk lung 2023
-
6:58
strategies to overcome resistance - lung cancer onctalk 2022
-
2:32
segmentectomy for early stage nsclc - onctalk lung 2023
-
1:44
extended interval dosing for pembrolizumab - lung cancer onctalk 2022
-
6:26
systemic and local therapies for metastatic disease - lung cancer onctalk 2022
-
2:59
q&a: how do oncologists determine oligoprogressive status? - onctalk lung 2023
-
4:29
studies in chemoimmunotherapy - lung cancer onctalk 2022
-
2:18
treatment of stage iv nsclc with high pd-l1 and atypical mutation - lung cancer onctalk 2022
-
3:03
stereotactic body radiation therapy (sbrt) for medically inoperable early stage lung cancer
-
2:39
grace targeted therapies lung cancer 2021 - return to alectinib -progression on lorlatinib in alk
-
4:56
dual immune checkpoint blockade with or without chemotherapy - lung cancer onctalk 2022
-
8:03
studies in anti-pd-l1 monotherapy for nsclc - lung cancer onctalk 2022
-
1:48
preoperative or postoperative immunotherapy? - lung cancer onctalk 2022